New Zealand Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the New Zealand Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

New Zealand Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Innovative pharmaceutical firms will see limited upsides from New Zealand's newly adopted health strategy for the next decade. Cost rationalisation remains a cornerstone of the government's approach and affirms the pharmaceutical management agency's stringent control on pharmaceutical spending. Drugmakers will also have to adapt to shifts in patient flow as New Zealand seeks to encourage the delivery of medical services within local communities.

Headline Expenditure Forecasts

  • Pharmaceuticals : NZD1.48bn (USD1.0bn) in 2015 to NZD1.51bn (USD982mn) in 2016; 2.0% in local currency terms and -4.9% in US dollar terms.

  • Healthcare: NZD27.42bn (USD19.13bn) in 2015 to NZD28.41bn (USD18.47bn) in 2016; 3.6% in local currency terms and -3.5% in US dollar terms.

Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
*figures rounded to two decimal places. f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn* 1.200 1.030 0.980 0.950 0.940 0.960 0.980
Pharmaceutical sales, % of GDP 0.61 0.60 0.60 0.59 0.58 0.57 0.55
Pharmaceutical sales, % of health expenditure 5.5 5.4 5.3 5.2 5.2 5.1 5.0
Health spending, USDbn* 21.940 19.130 18.470 18.100 18.290 18.940 19.620

Risk/Reward Index

In BMI's Q3 2016 Pharmaceutical Risk/Reward Index (RRI), New Zealand has climbed up one place from its Q216 position, coming in at ninth out of 19 markets. With a score of 51.0 out of 100, the country is now ranked below the regional average of 52.3. A strong and predictable environment of low operating risks are weighed down by a small market and low potential for growth relative to other markets in the region.

Latest Updates

  • In April 2016, New Zealand's government launched a new health strategy. This represents an update to the existing approach which was put in place in 2000. Underpinning this strategy are five key themes; people-powered, closer to home; value and high performance; one team; and smart system.

  • Local news sources reported in May 2016 that despite Merck Sharp & Dohme's submission of new data for Keytruda (pembrolizumab), the New Zealand government will continue to recommend that funding for the treatment receive a lower priority. According to New Zealand's Health Minister, Jonathan Coleman, this additional evidence referenced by the firm has not been peer-reviewed.

That same month, the government announced that the pharmaceutical management agency will receive an extra NZD39mn to help fund Opdivo (nivolumab) for approximately 350 patients. Money will also be spent on funding treatments for hepatitis C such as Harvoni (sofosbuvir and ledipasvir) and Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir).

BMI Economic View

New Zealand's real GDP growth in q-o-q seasonally adjusted, annualised terms picked up to 4.9% in Q315 (versus 2.8% q-o-q in Q215) due to strong growth in manufacturing and services. However, we are revising down our 2016 real GDP forecast to 2.3% (versus 2.5% previously) given the significant downside risks to economic activity in the agriculture and construction sectors.

BMI Political View

Wellington's lifting of UN sanctions against Iran on February 18 will be positive for New Zealand as Iran has the potential to become a new dairy market amid slowing Chinese demand. The country's positive image in Iran will further help boost the efforts of New Zealand businesses, benefitting the country's exporters

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2014-2020)
7
SWOT
9
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2012-2020)
12
Healthcare Market Forecast
13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
15
Prescription Drug Market Forecast
16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
17
Patented Drug Market Forecast
18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
19
Generic Drug Market Forecast
20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
21
OTC Medicine Forecast
22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
23
Pharmaceutical Trade Forecast
24
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2014-2020)
25
Table: Pharmaceutical Trade Data And Forecasts local currency (New Zealand 2014-2020)
25
Industry Risk Reward Index
26
Asia Pacific Risk/Reward Index
26
New Zealand Risk/Reward Index
32
Rewards
32
Risks
32
Regulatory Review
34
Regulatory Development
34
Intellectual Property Issues
34
Pricing & Reimbursement Regime
35
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
40
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
41
Market Overview
43
Healthcare Sector
44
Table: Healthcare Resources (New Zealand 2010-2015)
45
Table: Healthcare Activity (New Zealand 2010-2015)
46
Table: Healthcare Personnel (New Zealand 2010-2015)
46
Research & Development
47
Clinical Trials
47
Epidemiology
49
Competitive Landscape
53
Research-Based Industry
53
Table: Multinational Market Activity
54
Pharmaceutical Distribution
54
Pharmaceutical Retail Sector
55
Company Profile
57
Douglas Pharmaceuticals
57
New Zealand Pharmaceuticals
60
Pfizer New Zealand
62
Demographic Forecast
64
Table: Population Headline Indicators (New Zealand 1990-2025)
65
Table: Key Population Ratios (New Zealand 1990-2025)
65
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025)
66
Table: Population By Age Group (New Zealand 1990-2025)
66
Table: Population By Age Group % (New Zealand 1990-2025)
67
Glossary
69
Methodology
71
Pharmaceutical Expenditure Forecast Model
71
Healthcare Expenditure Forecast Model
71
Notes On Methodology
72
Risk/Reward Index Methodology
73
Index Overview
74
Table: Pharmaceutical Risk/Reward Index Indicators
74
Indicator Weightings
75

The New Zealand Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's New Zealand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the New Zealand pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for New Zealand, to test other views - a key input for successful budgeting and strategic business planning in the New Zealand pharmaceutical and healthcare market.
  • Target business opportunities and risks in the New Zealand pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in New Zealand.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.